Orthogonal Neuroscience

Orthogonal Neuroscience Inc. is a developer of novel therapeutics designed to treat neurodegenerative diseases including potential treatments for CMT.

Through a CMTA Preclinical Testing Alliance, Orthogonal has gained access to CMTA’s service research providers and network. CMTA provided bespoke support around selection of appropriate models, design of the experiments, data interpretation and guidance regarding what future experiments would be needed to take the project forward. CMTA also made introductions to key clinicians and thought leaders to facilitate future clinical trials in CMT patients. CMTA Preclinical Testing Alliance facilitated ORT247 tests in 1A (demyelinating) and 2E (axonopathy) CMT models and the results show an improvement in several disease endpoints.